Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,988.00
Bid: 12,016.00
Ask: 12,020.00
Change: -38.00 (-0.32%)
Spread: 4.00 (0.033%)
Open: 12,070.00
High: 12,144.00
Low: 11,882.00
Prev. Close: 12,026.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks Start Lower Ahead Of Trump Press Conference

Fri, 29th May 2020 08:51

(Alliance News) - Stock prices in London opened in the red on Friday, as worsening US–China relations overshadow optimism from the easing of coronavirus lockdowns across the globe.

The FTSE 100 index was down 36.50 points, or 0.6%, at 6,182.29 on Friday. Since the week began, the blue-chip index is up 2.8%, though it remains down 18% so far in 2020.

The mid-cap FTSE 250 index was down 58.89 points, or 0.3%, at 17,279.59, and the AIM All-Share index was down 0.2% at 873.60.

The Cboe UK 100 index was 0.8% lower at 10,446.43. The Cboe 250 was down 0.4% at 14,781.40, and the Cboe Small Companies down 0.1% at 12,120.78.

In mainland Europe, the CAC 40 in Paris was down 0.8%, while the DAX 30 in Frankfurt was down 1.1%.

"Risk-off is dominating as investors look ahead to Trump's response, provoked by China's crackdown on civil liberties in Hong Kong, Asia's financial hub," said City Index analyst Fiona Cincotta.

Trump said he will give a press conference Friday on China amid rising US-Chinese tensions over Hong Kong and the coronavirus fallout.

Trump told reporters of his plan for the press conference at an Oval Office meeting on Thursday, but gave no specific details of what he would be announcing.

Fears that China will use a new law to end Hong Kong's freedom as a semi-autonomous territory have prompted expectations that Trump plans to hit back, possibly signalling a wider economic confrontation between the two superpowers.

Washington and Beijing are already clashing over responsibility for the extent of the coronavirus pandemic, which originated in China but has caused devastation in the US. The US recorded 1,297 coronavirus deaths on Thursday, bringing its total to 101,573 since the global pandemic began, according to a tally kept by Johns Hopkins University.

The country has officially logged 1.7 million cases of the virus, far more than any other nation, the tracker kept by the Baltimore-based university showed. Trump blames that on China, although his domestic critics accuse him of mismanagement.

"The fear is that the US–China spat could hamper a fragile economic recovery from the coronavirus crisis," added Cincotta.

The Hang Seng index in Hong Kong closed down 0.7% on Friday. Elsewhere in China, the Shanghai Composite finished up 0.2%. In Japan, Tokyo's Nikkei 225 index closed down 0.2%.

On the London Stock Exchange, AstraZeneca was among the best performers in the blue-chip index, up 1.3%, after its phase 3 Adaura trial of Tagrisso in early-stage cell lung cancer found that the drug reduced the risk of disease recurrence or death by around 80%.

The detailed results were from a trial of Tagrisso, the brand name for osimertinib, after surgery in patients with "epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer after complete tumour resection with curative intent". EGFR mutations are associated with some lung cancers.

In the primary endpoint of disease-free survival in patients with stage 2 and 3A disease, treatment with Tagrisso reduced risk of disease recurrence or death by 83%. Disease-free survival in the overall trial population, covering stages 1B to 3A, found a 79% drop in the risk of disease recurrence or death.

At the two year mark, 89% of patients in the trial who had been treated with Tagrisso were still alive and disease free compared to a 53% figure in patients who were given a placebo.

Admiral Group was among the worst performers on Friday morning, down 1.6%, after Barclays cut the insurer to Equal Weight from Overweight.

Fresnillo was trading 1.5% lower after saying that it is responding to operational challenges caused by Covid-19 after a tough 2019. The Mexican gold miner said it has focused on responding to the Covid-19 over the past three months, implementing a range of safety measures across the business.

"Up to this point, we have had no officially confirmed Covid-19 cases originating from inside our operations," said Chair Alberto Bailleres. However, he noted that three colleagues were officially diagnosed from exposure outside.

Fresnillo also confirmed that the board and senior management took voluntary and temporary pay cuts to help the company get through this "unprecedented" situation.

Fresnillo said its operations are critical to the economies in which it operate, with mining now confirmed as an essential activity in Mexico.

"Operationally, 2019 was a more challenging year, as expected," said Bailleres.

Both silver and gold production fell from 2018 levels, due to lower-than-anticipated grades in its key mines. This also hurt Fresnillo's financial performance.

In the face of these operational challenges, the company said its response has been to increase the pace and scale of investments in a series of projects and take corrective actions to bring production back to acceptable levels in the short-term, and to achieve steady growth in future years.

"We are investing in infrastructure, plant and machinery including a state-of-the-art tunnel boring machine which is now being ramped up at Fresnillo - one of the first of its kind. We have also begun to define a new programme to control costs and increase productivity," said Bailleres.

Among the mid-caps, Provident Financial was the best performer, up 4.4% in early trade, after getting an upgrade from Jefferies to Buy from Hold.

B&M European Value Retail was the second-best performer in the FTSE 250 index, up 3.6%. B&M reported a strong end to the fourth quarter - which ran to March 28 - driven by exceptionally strong March performance in Grocery, with the B&M UK fascia like-for-like revenue up 6.6%.

Going forward, B&M said it experienced strong revenue growth in the first 8 weeks to May 23, with B&M UK fascia like-for-like revenue up 23%, driven by exceptionally strong Do It Yourself and Gardening categories, and despite a significant fall in customer count.

If DIY and Gardening categories are excluded, the B&M UK fascia like-for-like revenue over that 8 week period was up 10%.

"We have encountered exceptionally strong demand in our UK business over recent weeks. Customers have been coming to our stores much less frequently through the lockdown but their average spend has been much higher than normal," said Chief Executive Simon Arora.

"Clearly, there is also considerable uncertainty in relation to both the progression of Covid-19 and the economic outlook, and it is therefore hard to predict future trading levels," added Arora.

SIG was up 3.6% in the morning trading on Friday. The building products supplier announced plans to bring in a substantial new investor as part of an equity fundraise to deliver a new growth strategy, after swinging to a loss in 2019.

SIG reported a 9.0% decline in revenue in 2019 to GBP2.08 billion. On a like-for-like basis, sales declined by 7.6%.

SIG said its performance was hurt by market share losses in UK and Germany due to poor execution of transformation initiatives which, it believes, disconnected the business from its customers, suppliers and its front-line colleagues.

As a result, the company swung to pretax loss of GBP112.7 million in 2019 compared to GBP10.3 million profit a year prior.

SIG cut its dividend to 1.25 pence, having paid a 3.75p per share payout in 2018.

"The 2019 results, albeit in line with January guidance, are disappointing. However, the board has taken decisive action to address this performance. A new chief executive has been appointed and, this morning, we announced the appointment of a new chief financial officer," said Chair Andrew Allner.

SIG named Ian Ashton as permanent CFO and Simon King as a non-executive director, both with effect from the start of July.

Ashton replaces Kath Kearney-Croft, who had taken on the role of interim CFO back in February. Ashton will join SIG from Low & Bonar, where he has served as CFO.

Going forward, SIG said it has explored its wider funding options and is intending to raise GBP150 million in new equity in the coming weeks to strengthen its capital structure and enable the management team to deliver its new growth strategy. The equity raise will be led by US private equity firm Clayton, Dubilier & Rice, which will contribute up to GBP85 million and take an about 25% stake in SIG as a result.

In commodities, gold was quoted at USD1,721.98 an ounce early Friday, soft from USD1,722.65 late Thursday. Brent oil was at USD35.08 a barrel, up from USD34.45.

"Safe haven gold is building on gains from the previous session as tensions between the US and China mount, although the US dollar is slipping lower, decoupling from falling stocks," said City Index's Cincotta.

Against the yen, the dollar was trading at JPY107.19 early Friday in London, down from JPY107.60 late Thursday.

The pound was quoted at USD1.2350 early Friday, firm from USD1.2323 at the London equities close Thursday. The euro was at USD1.1100 early Friday, up from USD1.1067 late Thursday.

German retail sales slumped in April, the latest data from Destatis showed on Friday, with a separate release showing import prices also sank.

Retail sales were down 5.3% on a monthly basis and 6.5% annually in April, far steeper than falls of 4.0% and 1.2% recorded, respectively, for March.

Separately, the statistical body showed import prices were down 7.4% in April year-on-year, the sharpest fall recorded since 2009. In March, prices had fallen 5.5%.

The economic events calendar on Friday has eurozone inflation figures at 1000 BST. In the London afternoon, there are US personal consumption expenditure index numbers at 1330 BST - the core reading is the US Federal Reserve's preferred gauge of inflation.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.